Steroids in the treatment of iga nephropathy to the improvement of renal survival: A systematic review and meta-analysis

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Zhou, Yu Hao ^a   Tang, Li Gong ^c   Guo, Shi Lei ^a   Jin, Zhi Chao ^a   Wu, Mei Jing ^a   Zang, Jia Jie ^a   Xu, Jin Fang ^a   Wu, Chun Fang ^a   Qin, Ying Yi ^a   Cai, Qing ^b   Gao, Qing Bin ^a   Zhang, Shan Shan ^a   Yu, Dand Hui ^a   He, Jia ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; CILAZAPRIL; CREATINE; DIPYRIDAMOLE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PROTEIN; RAMIPRIL; STEROID; THROMBOCYTE ANTIBODY; CORTICOSTEROID; CREATININE;

ARTICLE; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; META ANALYSIS; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; STEROID THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION; BLOOD; KIDNEY FUNCTION TEST; PATHOPHYSIOLOGY; PROTEINURIA; REVIEW;

ADRENAL CORTEX HORMONES; CREATININE; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY FUNCTION TESTS; PROTEINURIA;

EID: 79954500096     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018788     Document Type: Article

References (47)

1. Julian BA, Waldo FB, Rifai A, Mestecky J, (1988) IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? Am J Med 84: 129-32.
2. Cheng KP, Fang GX, Wong MC, Ji YL, Chan KW, et al. (1998) A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in Ig A nephropathy. Nephrology 4: 19-26.
3. D' Amico G, (1987) The commonest glomerulonephritis in the world: Ig A nephropathy. Q J Med 64: 709-727.
4. Tomiyoshi Y, Sakemi T, Ikeda Y, Ohtsuka Y, Nakamura M, et al. (2001) Cellular crescents and segmental glomerular necrosis in Ig A nephropathy are indicative of the beneficial effects of corticosteroid therapy. Intern Med 40: 862-866.
5. Levy M, Berger J, (1988) Worldwide perspective of IgA nephropathy. Am J Kidney Dis 12: 340-347.
6. Schena FP, (2001) Immunoglobulin A nephropathy with mild renal lesion: a call in the forest for physicians and nephrologists. Am J Med 110: 499-500.
7. Droz D, (1976) Natural history of primary glomerulonephritis with mesangial deposits of IgA. Contrib Nephrol 12: 150-156.
8. D'Amico G, Colosanti G, Barbiano diBelg, Fellin G, Ragni A, et al. (1987) Long-term follow-up of IgA mesangial nephropathy: cliníco-histological study in 374 patients. Semin Nephrol 7: 355-358.
9. Monteiro RC, (2005) New insights in the pathogenesis of Ig A nephropathy. Nefrologia 2: 82-86.
10. Mestecky J, Tomana M, Crowley-Nowick PA, Moldoveanu Z, Julian BA, et al. (1993) Defective galactosilation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol 104: 172-82.
11. D'amico G, (1997) Treatment of IgA nephropathy: An overview. Nephrology 2: 725-730.
12. Harmankaya O, Ozturk Y, Basturk T, Obek A, Kilicarslan I, (2002) Efficacy of immunosuppressive therapy in Ig A nephropathy presenting with isolated hematuria. Int Urol Nephrol 33: 167-171.
13. Nolin L, Courteau M, (1999) Management of Ig A nephropathy: Evidence-based recommendations. Kidney Int 70: 56-62.
14. Gutierrez E, Gonzalez E, Hernandez E, Morales E, Martinez MA, et al. (2007) Factors that determine an incomplete recovery of renal function in Macrohematuria-induced acute renal failure of Ig A nephropathy. Clin J Am Soc Nephrol 2: 51-57.
15. Gallo GR, Katafuchi R, Neelakantappa K, Baldwin DS, (1988) Prognostic pathologic markers in IgA nephropathy. Am J Kidney Dis 12: 363-5.
16. Laville M, Alamartine E, (2004) Treatment options for Ig A nephropathy in adults: a proposal for evidence-based strategy. Nephrol Dial Transplant 19: 1947-1951.
17. Neelakantappa K, Gallo GR, Baldwin DS, (1988) Proteinuria in IgA nephropathy. Kidney Int 33: 716-21.
18. Barratt J, Feehally J, (2006) Treatment of Ig A nephropathy. Kidney Int 11: 1934-1938.
19. Hodson EM, Willis NS, Craig JC, (2006) Corticosteroid therapy for nephrotic syndrome in children. Cochrane Db Syst Rev 1: 1240-1296.
20. Strippoli GFM, Manno C, Schena FP, (2003) An "evidence-based" survey of therapeutic options for Ig A nephropathy: assessment and criticism. Am J Kidney Dis 41: 1129-1139.
21. Manno C, Torres DD, Rossini M, Pesce F, Schena FP, (2009) Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric Ig A nephropathy. Nephrol Dial Transpl 12: 3694-3701.
22. Lv J, Zhang H, Chen Y, Li G, Jiang L, et al. (2009) Combination Therapy of Prednisone and ACE Inhibitor versus ACE-Inhibitor Therapy Alone in Patients With IgA Nephropathy: A Randomized Controlled Trial. Am J Kidney Dis 53: 26-32.
23. Higgins J, Altman DG, (2008) Assessing risk of bias in included studies. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 Oxford, England Cochrane Collaboration: chap 8.
24. Shimizu A, Takei T, Uchida K, Tsuchiya K, Nitta K, (2009) Predictors of poor outcomes in steroid therapy for immunoglobulin A nephropathy. Nephrology 14: 521-526.
25. Waldo FB, Wyatt RJ, Kelly DR, Herrera GA, Benfield MR, et al. (1993) Treatment of Ig A nephropathy in children: efficacy of alternate-day oral prednisone. Pediatr Nephrol 5: 529-532.
26. Ohashi T, Shimokawahara H, (1992) Effects of steroid therapy in Ig A nephropathy. Fukuoka lgaku zasshi 5: 209-215.
27. Deeks JJ, Higgins JPT, Altman DG, (2008) Analyzing data and undertaking meta-analyses. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 Oxford, UK The Cochrane Collaboration: chap 9.
28. Katafuchi R, Ninomiya T, Mizumasa T, Ikeda K, Kumagai H, et al. (2008) The improvement of renal survival with steroid pulse therapy in IgA nephropathy. Nephrol Dial Transpl 23: 3915-3920.
29. Koike M, Takei T, Uchida K, Honda K, Moriyama T, et al. (2008) Clinical assessment of low-dose steroid therapy for patients with IgA nephropathy: a prospective study in a single center. Clin Exp Nephrol 12: 250-255.
30. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, et al. (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: 157-163.
31. Moriyama T, Honda K, Nitta K, Yumura W, Nihei H, (2004) The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function. Clin Exp Nephrol 8: 237-242.
32. Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, et al. (2003) Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis 5: 972-983.
33. Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, et al. (2000) Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 2: 194-201.
34. Lai KN, Lai FM, Ho CP, Chan KW, (1986) Corticosteroid therapy in IgA nephropathy with nephrotic sydrome: A long-term controlled trial. Clin Nephrol 4: 174-180.
35. Kobayashi Y, Hiki Y, Kokubo T, Horri A, Tateno S, (1996) Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephrol 72: 237-242.
36. Welch TR, Fryer C, Shely E, Witte DP, Quinlan M, (1992) Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr 121: 474-477.
37. Kobayashi Y, Hiki Y, Fujii K, Kurokawa A, Kamiyama M, et al. (1988) Effect of corticosteroids on renal function in progressive IgA nephropathy- Long-term follow-up study. Nippon Jinzo Gakkai Shi 9: 73-80.
38. Julian BA, Barker C, (1993) Alternate-day prednisone therapy in IgA nephropathy: Preliminary analysis of a prospective, randomized, controlled trial. Contrib Nephrol 104: 198-206.
39. Uzu T, Harada T, Ko M, Yamato M, Takahara K, et al. (2003) Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria. Clin Exp Nephrol 7: 210-214.
40. Locatelli F, Pozzi C, Del Vecchio L, Bolasco PG, Fogazzi GB, et al. (2001) Role of proteinuria reduction in the progression of Ig A nephropathy. Ren fail 23: 495-505.
41. Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, et al. (2005) Multivariate analysis of prognostic factors and effect of treatment in patients with Ig A nephropathy. Ren fail 1: 45-52.
42. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, et al. (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353: 883-887.
43. Appel GB, Waldman M, (2006) The Ig A nephropathy treatment dilemma. Kidney Int 69: 1939-1944.
44. Bender R, Bunce C, Clarke M, Simon G, Stefan L, et al. (2008) Attention should be given to multiplicity issues in systematic reviews. J Clin Epidemiol 61: 857-865.
45. Guyatt GH, Wyer P, Ioannidis J, (2008) When to believe a subgroup analysis. In: Guyatt G, Rennie R, Meade M, Cook D, editors. User's Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice New York, NY McGraw-Hill.
46. Cheng J, Zhang X, Zhang W, He Q, Tao X, et al. (2009) Efficacy and Safety of Glucocorticoids Therapy for IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials. Am J Nephrol 30: 315-322.
47. Knechtle SJ, (2003) Clinical trials: Where are we now? Immunol Rev 196: 237-246.